Clinical characteristics and treatment outcomes in acromegaly, a retrospective single-center case series from Thailand
- PMID: 34795812
- PMCID: PMC8571915
- DOI: 10.11604/pamj.2021.40.31.29920
Clinical characteristics and treatment outcomes in acromegaly, a retrospective single-center case series from Thailand
Abstract
Introduction: acromegaly, an overproduction of growth hormone (GH), is associated with high rate of morbidity and mortality particularly in case of delayed in diagnosis and treatment. A wide variation of clinical presentations, treatment outcomes and morbidities have been reported.
Methods: a retrospective study was conducted to review clinical characteristics and treatment outcomes of patients with acromegaly treated in King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between 2006 and 2018.
Results: eighty-four patients (31 males and 53 females) were reviewed, mean age at diagnosis was 45.7 ± 12.6 years (±SD), mean time of disease onset was 7.6 ± 6.4 years and mean follow-up period was 7.8 ± 5.3 years. The most common presenting symptoms were maxillofacial change (96.8%) and acral enlargement (94.7%). Hypertension (39.3%), diabetes mellitus (28.6%) and dyslipidemia (23.8%) were prevalent co-existing conditions. Four patients were identified having cancer at presentation; however, no additional malignancy was reported during the follow up. Most patients harbored macroadenomas, only 10 were found to have microadenomas. The outcomes of treatment were controlled disease in 70% of microadenoma and 64.9% of macroadenoma. Permanent loss of pituitary function was found in about 21.3% and there was one case reported of mortality. The logistic regression analysis for controlled disease outcome showed the IGF-I index after surgery was associated with controlled disease outcome with statistically significant result (P-value=0.006).
Conclusion: our study offers descriptive clinical data of case series of acromegalic patients, which had favorable outcomes comparable with previous reports. In addition, IGF-I index after surgery is a predictive parameter for outcome of treatment.
Keywords: Acromegaly; gigantism; pituitary tumor.
Copyright: Poranee Ganokroj et al.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.Neurosurg Focus. 2020 Jun;48(6):E10. doi: 10.3171/2020.3.FOCUS2080. Neurosurg Focus. 2020. PMID: 32480366
-
Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University.Intern Med. 2001 Oct;40(10):987-92. doi: 10.2169/internalmedicine.40.987. Intern Med. 2001. PMID: 11688841
-
Acromegaly.Pituitary. 2006;9(4):297-303. doi: 10.1007/s11102-006-0409-4. Pituitary. 2006. PMID: 17077948 Review.
-
Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease.Horm Res. 2004;62(6):293-9. doi: 10.1159/000082032. Epub 2004 Nov 10. Horm Res. 2004. PMID: 15542931
-
Characteristics and treatment outcomes of micromegaly - acromegaly with apparently normal basal GH: A retrospective study and literature review.Endocr Regul. 2022 Apr 30;56(2):87-94. doi: 10.2478/enr-2022-0010. Endocr Regul. 2022. PMID: 35489048 Review.
Cited by
-
Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines.Pituitary. 2023 Aug;26(4):319-332. doi: 10.1007/s11102-023-01322-7. Epub 2023 May 20. Pituitary. 2023. PMID: 37210433 Free PMC article.
-
Let's focus more on regional diversity of acromegaly.Ann Transl Med. 2022 Aug;10(16):848. doi: 10.21037/atm-22-3653. Ann Transl Med. 2022. PMID: 36111053 Free PMC article. No abstract available.
-
Clinical Profile and Treatment Outcomes in Patient with Acromegaly Using 14th Acromegaly Consensus Criteria.Indian J Endocrinol Metab. 2025 Mar-Apr;29(2):195-201. doi: 10.4103/ijem.ijem_522_24. Epub 2025 Apr 29. Indian J Endocrinol Metab. 2025. PMID: 40416459 Free PMC article.
References
-
- Katznelson L, Laws ER, Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951. - PubMed
-
- Plengpanich W, Mangkala J, Buranasukajorn P, Boonruang K, Sunthornyothin S, Suwanwalaikorn S, et al. Normal reference range of serum insulin-like growth factor (IGF)-I in healthy Thai adults. J Med Assoc Thai. 2008;91(11):1681–1684. - PubMed
-
- Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167(2):189–98. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous